{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T22:58:44Z","timestamp":1791932324842,"version":"4.3.4"},"reference-count":87,"publisher":"Elsevier BV","issue":"28","license":[{"start":{"date-parts":[[2011,6,1]],"date-time":"2011-06-01T00:00:00Z","timestamp":1306886400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1016\/j.vaccine.2011.04.055","type":"journal-article","created":{"date-parts":[[2011,5,8]],"date-time":"2011-05-08T14:17:28Z","timestamp":1304864248000},"page":"4544-4555","source":"Crossref","is-referenced-by-count":44,"title":["Active and passive surveillance of yellow fever vaccine 17D or 17DD-associated serious adverse events: Systematic review"],"prefix":"10.1016","volume":"29","author":[{"given":"Roger E.","family":"Thomas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane L.","family":"Lorenzetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Spragins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dave","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler","family":"Williamson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.vaccine.2011.04.055_bib0005","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1016\/j.vaccine.2006.12.015","article-title":"17D yellow fever vaccines: new insights. A report of a workshop held during the World Congress on medicine and health in the tropics, Marseille, France, Monday 12 September 2005","volume":"25","author":"Barrett","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0010","unstructured":"Meeting of Global Advisory Committee on Vaccine Safety, 18\u201319 June 2008. Wkly Epidemiol Rec 2008;83(32):287\u201392."},{"issue":"11","key":"10.1016\/j.vaccine.2011.04.055_bib0015","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1086\/587844","article-title":"Immune response during adverse events after 17D-derived yellow fever vaccination in Europe","volume":"197","author":"Bae","year":"2008","journal-title":"J Infect Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2011.04.055_bib0020","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.4269\/ajtmh.2009.09-0295","article-title":"Incidence of yellow fever vaccine-associated neurotropic disease","volume":"81","author":"Guimard","year":"2009","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vaccine.2011.04.055_bib0025","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S0091-6749(99)70245-9","article-title":"Anaphylaxis from yellow fever vaccine","volume":"103","author":"Kelso","year":"1999","journal-title":"J Allergy Clin Immunol"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2011.04.055_bib0030","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.vaccine.2004.01.026","article-title":"Viscerotropic and neurotropic disease following vaccination with the 17D yellow fever vaccine, ARILVAX","volume":"22","author":"Kitchener","year":"2004","journal-title":"Vaccine"},{"issue":"44","key":"10.1016\/j.vaccine.2011.04.055_bib0035","first-page":"989","article-title":"Centers for Disease Control and Prevention (CDC). Adverse events associated with 17D-derived yellow fever vaccination \u2013 United States, 2001\u20132002","volume":"51","author":"Levy","year":"2002","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"48","key":"10.1016\/j.vaccine.2011.04.055_bib0040","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination","volume":"26","author":"Lindsey","year":"2008","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2011.04.055_bib0045","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1016\/j.vaccine.2006.11.027","article-title":"Neurologic disease associated with 17D-204 yellow fever vaccination: a report of 15 cases","volume":"25","author":"McMahon","year":"2007","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0050","series-title":"Vaccines","first-page":"959","article-title":"Yellow fever vaccine","author":"Monath","year":"2008"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0055","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1017\/S0950268804002602","article-title":"Risk of fatal adverse events associated with 17DD yellow fever vaccine","volume":"132","author":"Struchiner","year":"2004","journal-title":"Epidemiol Infect"},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0060","doi-asserted-by":"crossref","first-page":"333","DOI":"10.4269\/ajtmh.2006.75.333","article-title":"Yellow fever vaccine-associated viscerotropic disease (YEL-AVD) and corticosteroid therapy: eleven United States cases, 1996\u20132004","volume":"75","author":"Vellozzi","year":"2006","journal-title":"Am J Trop Med Hyg"},{"issue":"43","key":"10.1016\/j.vaccine.2011.04.055_bib0065","doi-asserted-by":"crossref","first-page":"5974","DOI":"10.1016\/j.vaccine.2009.07.082","article-title":"Viscerotropic disease following yellow fever vaccination in Peru","volume":"27","author":"Whittembury","year":"2009","journal-title":"Vaccine"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2011.04.055_bib0070","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0264-410X(02)00449-8","article-title":"The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI)","volume":"21","author":"Bonhoeffer","year":"2002","journal-title":"Vaccine"},{"issue":"5\u20136","key":"10.1016\/j.vaccine.2011.04.055_bib0075","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0264-410X(03)00511-5","article-title":"Standardized case definitions of adverse events following immunization (AEFI)","volume":"22","author":"Bonhoeffer","year":"2004","journal-title":"Vaccine"},{"issue":"28","key":"10.1016\/j.vaccine.2011.04.055_bib0080","doi-asserted-by":"crossref","first-page":"4487","DOI":"10.1016\/j.vaccine.2010.04.041","article-title":"Can the Brighton Collaboration case definitions be used to improve the quality of adverse event following immunization (AEFI) reporting? Anaphylaxis as a case study","volume":"28","author":"Gold","year":"2010","journal-title":"Vaccine"},{"issue":"April 6 (16)","key":"10.1016\/j.vaccine.2011.04.055_bib0085","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.vaccine.2008.11.035","article-title":"Guidelines for collection, analysis and presentation of vaccine safety data in surveillance systems","volume":"27","author":"Bonhoeffer","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0090","unstructured":"Council for International Organizations of Medical Sciences (CIOMS). Reporting form for international reporting of adverse drug reactions. CIOMS 2011. Available from: URL: http:\/\/www.cioms.ch."},{"key":"10.1016\/j.vaccine.2011.04.055_bib0095","unstructured":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for clinical safety assessment (E2a-e). ICH 2011. Available from: URL: http:\/\/www.ich.org."},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0100","doi-asserted-by":"crossref","first-page":"189","DOI":"10.4269\/ajtmh.2005.72.189","article-title":"Randomized, double-blind, phase III, pivotal field trial of the comparative immunogenicity, safety, and tolerability of two yellow fever 17D vaccines (Arilvax and YF-VAX) in healthy infants and children in Peru","volume":"72","author":"Belmusto-Worn","year":"2005","journal-title":"Am J Trop Med Hyg"},{"issue":"1\u20132","key":"10.1016\/j.vaccine.2011.04.055_bib0105","first-page":"25","article-title":"Severe post-vaccination reaction to 17D yellow fever vaccine in Nigeria","volume":"45","author":"Oyelami","year":"1994","journal-title":"Rev Roum Virol"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0110","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/0035-9203(93)90156-K","article-title":"Yellow fever vaccination and pregnancy: a four-year prospective study","volume":"87","author":"Nasidi","year":"1993","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0115","unstructured":"WHO Emerging and Other Communicable Diseases. District guidelines for yellow fever surveillance. Geneva: World Health Organization; 1998. Report No.: WHO\/EPI\/GEN\/98.09."},{"issue":"7","key":"10.1016\/j.vaccine.2011.04.055_bib0120","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/0264-410X(94)90267-4","article-title":"Combined vaccination against yellow fever and typhoid fever: a comparative trial","volume":"12","author":"Ambrosch","year":"1994","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0125","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1590\/S0034-89102005000300012","article-title":"Reactogenicity of yellow fever vaccines in a randomized, placebo-controlled trial","volume":"39","author":"Camacho","year":"2005","journal-title":"Rev Saude Publica"},{"issue":"7","key":"10.1016\/j.vaccine.2011.04.055_bib0130","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1111\/j.1365-3156.2007.01851.x","article-title":"Campinas group of yellow fever immunization during P. Early exposure to yellow fever vaccine during pregnancy","volume":"12","author":"Cavalcanti","year":"2007","journal-title":"Trop Med Int Health"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0135","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1017\/S0022172400019653","article-title":"Vaccination by scarification with a combined 17D yellow fever and vaccinia vaccine","volume":"50","author":"Dick","year":"1952","journal-title":"J Hyg"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0140","first-page":"140","article-title":"A preliminary evaluation of the immunizing power of chick-embryo 17D yellow fever vaccine inoculated by scarification","volume":"55","author":"Dick","year":"1952","journal-title":"Am J Hyg"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0145","first-page":"84","article-title":"Yellow fever vaccination for the Jordanian peace keeping forces","volume":"38","author":"Edwan","year":"2004","journal-title":"Jordan Med J"},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0150","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.vaccine.2004.05.018","article-title":"Safety of the yellow fever vaccine during the September 2001 mass vaccination campaign in Abidjan, Ivory Coast","volume":"23","author":"Fitzner","year":"2004","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0155","first-page":"50","article-title":"A combined yellow fever-smallpox vaccine for cutaneous application","volume":"54","author":"Hahn","year":"1951","journal-title":"Am J Hyg"},{"issue":"6","key":"10.1016\/j.vaccine.2011.04.055_bib0160","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.4269\/ajtmh.1999.60.1045","article-title":"Comparison of the immunogenicity and safety of two 17D yellow fever vaccines","volume":"60","author":"Lang","year":"1999","journal-title":"Am J Trop Med"},{"issue":"January (1)","key":"10.1016\/j.vaccine.2011.04.055_bib0165","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0092-1157(89)90023-1","article-title":"Study of combined vaccination against yellow fever and measles in infants from six to nine months","volume":"17","author":"Lhuillier","year":"1989","journal-title":"J Biol Stand"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0170","doi-asserted-by":"crossref","first-page":"533","DOI":"10.4269\/ajtmh.2002.66.533","article-title":"Comparative safety and immunogenicity of two yellow fever 17D vaccines (ARILVAX and YF-VAX) in a phase III multicenter, double-blind clinical trial","volume":"66","author":"Monath","year":"2002","journal-title":"Am J Trop Med Hyg"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0175","doi-asserted-by":"crossref","first-page":"207","DOI":"10.4161\/hv.1.5.2221","article-title":"Yellow fever 17D vaccine safety and immunogenicity in the elderly","volume":"1","author":"Monath","year":"2005","journal-title":"Hum Vaccin"},{"issue":"4","key":"10.1016\/j.vaccine.2011.04.055_bib0180","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/S0092-1157(81)80036-4","article-title":"A clinical study of stabilized 17D strain live attenuated yellow fever vaccine","volume":"9","author":"Moss-Blundell","year":"1981","journal-title":"J Biol Stand"},{"issue":"11","key":"10.1016\/j.vaccine.2011.04.055_bib0185","first-page":"1056","article-title":"Antibody response to 17D yellow fever vaccine in Ghanaian infants","volume":"79","author":"Osei-Kwasi","year":"2001","journal-title":"Bull World Health Organ"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0190","first-page":"23","article-title":"Yellow fever vaccination (17-D) and allergy","volume":"50","author":"Panthier","year":"1957","journal-title":"Bull Soc Pathol Exot Filiales"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0195","series-title":"Abstracts of the interscience conference on antimicrobial agents and chemotherapy","first-page":"41","article-title":"Yellow fever vaccination during pregnancy","author":"Papaiordanou","year":"2001"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0200","doi-asserted-by":"crossref","first-page":"339","DOI":"10.4269\/ajtmh.2005.72.339","article-title":"Immunogenecity and safety of Berna-YF compared with two other 17D yellow fever vaccines in a phase 3 clinical trial","volume":"72","author":"Pfister","year":"2005","journal-title":"Am J Trop Med"},{"issue":"5 Pt 2","key":"10.1016\/j.vaccine.2011.04.055_bib0205","first-page":"772","article-title":"Reactions to vaccination against yellow fever","volume":"79","author":"Pivetaud","year":"1986","journal-title":"Bull Soc Pathol Exot Filiales"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0210","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0264-410X(86)90004-6","article-title":"Comparative clinical study of a new 17D thermostable yellow fever vaccine","volume":"4","author":"Roche","year":"1986","journal-title":"Vaccine"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0215","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4269\/ajtmh.1938.s1-18.437","article-title":"Yellow fever vaccination with cultured virus (17D) without immune serum","volume":"s1\u201318","author":"Smith","year":"1938","journal-title":"Am J Trop Med"},{"issue":"5 Pt. 5","key":"10.1016\/j.vaccine.2011.04.055_bib0220","first-page":"885","article-title":"A new combined vaccine against yellow fever and measles in infants aged 6 to 24 months in Mali","volume":"84","author":"Soula","year":"1991","journal-title":"Bull Soc Pathol Exot"},{"issue":"9","key":"10.1016\/j.vaccine.2011.04.055_bib0225","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/j.vaccine.2005.09.033","article-title":"Campinas group on yellow fever immunization during P. The effects of yellow fever immunization (17DD) inadvertently used in early pregnancy during a mass campaign in Brazil","volume":"24","author":"Suzano","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2011.04.055_bib0230","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/infdis\/126.4.362","article-title":"Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity in man","volume":"126","author":"Tauraso","year":"1972","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0235","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1086\/597006","article-title":"Immunogenicity and safety of yellow fever vaccination for 102 HIV-infected patients","volume":"48","author":"Veit","year":"2009","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0240","doi-asserted-by":"crossref","first-page":"437","DOI":"10.4269\/ajtmh.1938.s1-18.437","article-title":"Yellow fever vaccination with cultured virus (17D) without immune serum","volume":"s1\u201318","author":"Smith","year":"1938","journal-title":"Am J Trop Med"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0245","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2217\/hiv.09.52","article-title":"Yellow fever vaccination in HIV-infected patients","volume":"4","author":"Veit","year":"2010","journal-title":"HIV Therapy"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0250","unstructured":"Review of adverse events reported following use of yellow fever vaccine \u2013 Canada, 1987\u20132000. Can Commun Dis Rep 2002;28(2):9\u201315."},{"key":"10.1016\/j.vaccine.2011.04.055_bib0255","doi-asserted-by":"crossref","unstructured":"From the Centers for Disease Control and Prevention. Adverse events associated with 17D-derived yellow fever vaccination \u2013 United States, 2001\u20132002. JAMA 2002;288(20):2533\u20135.","DOI":"10.1001\/jama.288.20.2533-JWR1127-2-1"},{"issue":"10","key":"10.1016\/j.vaccine.2011.04.055_bib0260","first-page":"942","article-title":"Adverse events supposedly attributable to vaccination of yellow fever","volume":"31","author":"Bentancourt","year":"2008","journal-title":"Drug Safety"},{"issue":"17\u201318","key":"10.1016\/j.vaccine.2011.04.055_bib0265","doi-asserted-by":"crossref","first-page":"2349","DOI":"10.1016\/j.vaccine.2005.01.022","article-title":"Surveillance system of vaccine adverse events and local data analysis \u2013 the experience in a middle-sized city in Brazil, 1999\u20132001","volume":"23","author":"Fernandes","year":"2005","journal-title":"Vaccine"},{"issue":"16","key":"10.1016\/j.vaccine.2011.04.055_bib0270","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1016\/j.vaccine.2007.01.078","article-title":"Neurological adverse events temporally associated to mass vaccination against yellow fever in Juiz de Fora, Brazil, 1999\u20132005","volume":"25","author":"Fernandes","year":"2007","journal-title":"Vaccine"},{"issue":"25","key":"10.1016\/j.vaccine.2011.04.055_bib0275","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1016\/j.vaccine.2005.01.089","article-title":"Yellow fever vaccine: an updated assessment of advanced age as a risk factor for serious adverse events","volume":"23","author":"Khromava","year":"2005","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0280","first-page":"307","article-title":"Surveillance of adverse events following immunisation: Australia, 2000\u20132002","volume":"27","author":"Lawrence","year":"2003","journal-title":"Commun Dis Intell"},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0285","first-page":"244","article-title":"Age-related risk of adverse events following yellow fever vaccination in Australia","volume":"28","author":"Lawrence","year":"2004","journal-title":"Commun Dis Intell"},{"issue":"6","key":"10.1016\/j.vaccine.2011.04.055_bib0290","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3201\/eid0706.010605","article-title":"Advanced age a risk factor for illness temporally associated with yellow fever vaccination","volume":"7","author":"Martin","year":"2001","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0295","doi-asserted-by":"crossref","unstructured":"Martins RdeM, Maia MdeLdeS, dos Santos EM, Cruz RLdeS, dos Santos PRG, Carvalho SMD, et al. Yellow fever vaccine post-marketing surveillance in Brazil. Procedia Vaccinol 2010;2(2):178\u201383.","DOI":"10.1016\/j.provac.2010.07.012"},{"issue":"24","key":"10.1016\/j.vaccine.2011.04.055_bib0300","doi-asserted-by":"crossref","first-page":"4059","DOI":"10.1016\/j.vaccine.2010.04.002","article-title":"Surveillance for adverse events following immunization (AEFI) in Switzerland-1991\u20132001","volume":"28","author":"Schumacher","year":"2010","journal-title":"Vaccine"},{"issue":"29","key":"10.1016\/j.vaccine.2011.04.055_bib0305","doi-asserted-by":"crossref","first-page":"5253","DOI":"10.1016\/j.vaccine.2007.03.053","article-title":"Guillain\u2013Barre syndrome after vaccination in United States. A report from the CDC\/FDA Vaccine Adverse Event Reporting System","volume":"25","author":"Souayah","year":"2007","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0310","first-page":"181","article-title":"Encephalitis following anti-yellow fever vaccination (from 248 cases observed at Dakar in 1965)","volume":"14","author":"Diop Mar","year":"1967","journal-title":"Ann Pediatr (Paris)"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0315","first-page":"468","article-title":"The problem of post-yellow fever vaccination encephalitis","volume":"15","author":"Diop Mar","year":"1970","journal-title":"Bull Soc Med Afrique Noire Langue Francaise"},{"issue":"9276","key":"10.1016\/j.vaccine.2011.04.055_bib0320","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases","volume":"358","author":"Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0325","unstructured":"World Health Organization. Prevention and control of yellow fever in Africa. Geneva: World Health Organization; 1986."},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0330","first-page":"23","article-title":"Vaccination against yellow fever among patients on immunosuppressors with diagnoses of rheumatic diseases","volume":"42","author":"Da Mota","year":"2009","journal-title":"Rev Soc Bras Med Trop"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0335","first-page":"75","article-title":"The reaction to yellow fever vaccine (17D), particularly in allergic individuals","volume":"5","author":"Kouwenaar","year":"1953","journal-title":"Doc Med Geogr Trop"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0340","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/jnnp.73.3.348","article-title":"Risk of relapse of Guillain\u2013Barre syndrome or chronic inflammatory demyelinating polyradiculoneuropathy following immunisation","volume":"73","author":"Pritchard","year":"2002","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4898","key":"10.1016\/j.vaccine.2011.04.055_bib0345","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1136\/bmj.2.4898.1226-a","article-title":"Encephalitis after yellow fever vaccination","volume":"2","author":"Roodyn","year":"1954","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.vaccine.2011.04.055_bib0350","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0092-1157(86)90016-8","article-title":"Evaluation of thermostable yellow fever vaccine from the Pasteur Institute on international travellers","volume":"14","author":"Wolga","year":"1986","journal-title":"J Biol Stand"},{"issue":"4894","key":"10.1016\/j.vaccine.2011.04.055_bib0355","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1136\/bmj.2.4894.992-b","article-title":"Encephalitis after yellow-fever vaccination","volume":"2","author":"Haas","year":"1954","journal-title":"Br Med J"},{"issue":"4896","key":"10.1016\/j.vaccine.2011.04.055_bib0360","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1136\/bmj.2.4896.1108-a","article-title":"Encephalitis after yellow-fever vaccination","volume":"2","author":"Scott","year":"1954","journal-title":"Br Med J"},{"issue":"4892","key":"10.1016\/j.vaccine.2011.04.055_bib0365","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/bmj.2.4892.852","article-title":"Encephalitis in an infant after vaccination with 17 D yellow fever virus","volume":"2","author":"Smith","year":"1954","journal-title":"Br Med J"},{"issue":"4921","key":"10.1016\/j.vaccine.2011.04.055_bib0370","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1136\/bmj.1.4921.1090-b","article-title":"Encephalitis after yellow fever vaccination","volume":"1","author":"Cannon","year":"1955","journal-title":"Br Med J"},{"issue":"4","key":"10.1016\/j.vaccine.2011.04.055_bib0375","first-page":"537","article-title":"The combined measles-yellow fever vaccination in African infants aged 6 to 10 months","volume":"83","author":"Mouchon","year":"1990","journal-title":"Bull Soc Pathol Exot"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0380","unstructured":"Anonymous. Global advisory committee on vaccine safety, 16\u201317 June 2010. Wkly Epidemiol Rec 2010;85(30):285\u201391."},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0385","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1708-8305.2007.00175.x","article-title":"Impact of vaccines given during pregnancy on the offspring of women consulting a travel clinic: a longitudinal study","volume":"15","author":"D\u2019Acremont","year":"2008","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0390","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1046\/j.1365-3156.1998.00164.x","article-title":"Yellow fever vaccination during pregnancy and spontaneous abortion: a case\u2013control study","volume":"3","author":"Nishioka Sde","year":"1998","journal-title":"Trop Med Int Health"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0395","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0264-410X(98)00051-6","article-title":"Exposure to yellow fever vaccine in early pregnancy","volume":"17","author":"Robert","year":"1999","journal-title":"Vaccine"},{"issue":"6","key":"10.1016\/j.vaccine.2011.04.055_bib0400","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1093\/infdis\/168.6.1520","article-title":"Congenital yellow fever virus infection after immunization in pregnancy","volume":"168","author":"Tsai","year":"1993","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2011.04.055_bib0405","first-page":"145","article-title":"Good tolerance and efficacy of yellow fever vaccine among carriers of human immunodeficiency virus","volume":"2","author":"Goujon","year":"1995","journal-title":"J Travel Med"},{"issue":"1","key":"10.1016\/j.vaccine.2011.04.055_bib0410","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1089\/apc.2007.0059","article-title":"Vaccination in Brazilian HIV-infected adults: a cross-sectional study","volume":"22","author":"Ho","year":"2008","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.vaccine.2011.04.055_bib0415","unstructured":"Pacanowski J, Campa P, Dabrowska M, Lacombe K. Antibody response and safety of yellow fever vaccination in HIV infected patients. 48th Annual ICAAC (Washington, DC, October 25\u201328, 2008) 2008; Poster No. G 392."},{"key":"10.1016\/j.vaccine.2011.04.055_bib0420","first-page":"238","article-title":"Immunogenicity and safety of yellow fever vaccine in HIV-living travelers, France, 2005. (Special Issue: Travelers\u2019 health 2007.)","volume":"25\/26","author":"Pistone","year":"2007","journal-title":"Bull Epidemiol Hebd"},{"issue":"3","key":"10.1016\/j.vaccine.2011.04.055_bib0425","doi-asserted-by":"crossref","first-page":"E7","DOI":"10.1086\/314031","article-title":"Yellow fever vaccination of human immunodeficiency virus-infected patients: report of 2 cases","volume":"31","author":"Receveur","year":"2000","journal-title":"Clin Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2011.04.055_bib0430","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/00002030-200403260-00020","article-title":"Yellow fever vaccine is safe and effective in HIV-infected patients","volume":"18","author":"Tattevin","year":"2004","journal-title":"AIDS"},{"issue":"September (6)","key":"10.1016\/j.vaccine.2011.04.055_bib0435","doi-asserted-by":"crossref","first-page":"461","DOI":"10.2174\/157016210793499277","article-title":"Immunogenicity and tolerability of yellow fever vaccination in 23 French HIV-infected patients","volume":"8","author":"Pistone","year":"2010","journal-title":"Curr HIV Res"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11006001?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X11006001?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T16:25:04Z","timestamp":1560183904000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X11006001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,6]]},"references-count":87,"journal-issue":{"issue":"28","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["S0264410X11006001"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2011.04.055","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2011,6]]}}}